RENXF Renalytix plc
RENXF financial statements, revenue, balance sheet, cash flow, and SEC filings
▼ Company Profile
▼ Key Metrics (TTM)
As of Sep 30, 2024Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
| Metric | FY2024 📄 | FY2023 📄 | FY2022 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| Revenue | $2.29M | $3.40M | $2.97M |
| Cost of Revenue | $2.13M | $2.68M | $2.10M |
| Gross Profit | $156.00K | $720.00K | $874.00K |
| OPERATING EXPENSES | |||
| R&D Expense | $9.29M | $14.30M | $14.65M |
| SG&A Expense | $19.75M | $28.66M | $39.52M |
| Other Operating Expenses (derived) | $723.00K | $-19.00K | $-115.00K |
| Operating Income | $-29.61M | $-42.22M | $-53.18M |
| NON-OPERATING INCOME / EXPENSE | |||
| Other Income/Expense | $249.00K | $656.00K | - |
| Pretax Income | $-33.45M | $-45.61M | $-45.25M |
| Income Tax | $4.00K | $2.00K | $25.00K |
| Net Income | $-33.46M | $-45.61M | $-45.28M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $-0.31 | $-0.55 | $-0.67 |
| Diluted Shares | 108.18M | 82.21M | 73.84M |
| EBITDA | $-29.24M | $-41.71M | $-52.69M |
| Depreciation & Amortization | $364.00K | $508.00K | $489.00K |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $4.68M | $24.68M | $41.33M |
| Accounts Receivable | $722.00K | $776.00K | $901.00K |
| Other Current Assets | $716.00K | $1.42M | $2.45M |
| Current Assets | $6.12M | $26.88M | $44.75M |
| PP&E (Net) | $216.00K | $1.03M | $2.56M |
| Intangible Assets | $869.00K | $1.05M | $1.19M |
| Other Noncurrent Assets | $940.00K | $1.10M | - |
| Noncurrent Assets | $1.85M | $3.75M | $5.31M |
| Total Assets | $7.97M | $30.63M | $50.07M |
| LIABILITIES | |||
| Accounts Payable | - | - | $1.38M |
| Other Current Liabilities | $178.00K | $10.00K | $12.00K |
| Current Liabilities | $11.50M | $16.14M | $11.78M |
| Noncurrent Liabilities | $4.33M | $7.53M | $7.68M |
| Total Liabilities | $15.83M | $23.66M | $19.46M |
| EQUITY | |||
| Common Stock | $478.00K | $286.00K | $228.00K |
| Additional Paid-in Capital | $204.89M | $186.46M | $164.01M |
| Retained Earnings | $-211.78M | $-178.33M | $-132.72M |
| Accumulated OCI | $-1.44M | $-1.45M | $-915.00K |
| Total Equity | $-7.85M | $6.97M | $30.61M |
| Total Liabilities & Equity | $7.97M | $30.63M | $50.07M |
| SUPPLEMENTAL | |||
| Shares Outstanding | 154.37M | 93.78M | 74.76M |
| Check: A − (L + E + Temp. Equity) | - | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-30.11M | $-34.09M | $-45.92M |
| Capital Expenditures | - | $0 | $557.00K |
| Cash from Investing | $-4.00K | $0 | $-662.00K |
| Cash from Financing | $10.25M | $16.39M | $25.63M |
| Free Cash Flow | - | $-34.09M | $-46.48M |
| Beginning Cash (CFS) | $24.68M | $41.33M | $65.13M |
| Net Change in Cash | $-19.87M | $-17.70M | $-20.96M |
| Effect of FX on Cash | $-137.00K | $1.05M | $-2.84M |
| Calculated Ending Cash | $4.68M | $24.68M | $41.33M |
| Cash per BS | $4.68M | $24.68M | $41.33M |
| Cash scope difference (CFS − BS) | - | - | - |
| Cash per CFS | $4.68M | $24.68M | $41.33M |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log InQuarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
What is Renalytix plc's annual revenue?
Renalytix plc reported $2.35M in revenue for trailing twelve months (ending September 2024). Revenue figures are sourced from the company's annual SEC EDGAR filing.
Is Renalytix plc profitable?
No. Renalytix plc reported $-28.03M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.
Fundamentals Hub